Zalicus begins new human trial of reformulated pain drug

Zalicus Inc. ($ZLCS) is proceeding with a Phase I clinical trial of a new pain drug designed to use "multiple state-of-the-art" drug delivery techniques so it is more soluble and present in the body than in a previous version. The Cambridge, MA, company formally known as CombinatoRx said an earlier version of the novel oral N-type calcium channel blocker was tested in more than 200 patients. While that version may have been less soluble, the drug was well tolerated, Zalicus said. The new study will assess the drug's activity and safety through the end of 2011 and into early 2012. If all goes well, a Phase II trial for the drug will commence soon after, Zalicus President and CEO Mark Corrigan said in a statement. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.